The Invus Group Revenue and Competitors

Location

N/A

Total Funding

VC/PE

Industry

Estimated Revenue & Valuation

  • The Invus Group's estimated annual revenue is currently $15M per year.(i)
  • The Invus Group's estimated revenue per employee is $168,539

Employee Data

  • The Invus Group has 89 Employees.(i)
  • The Invus Group grew their employee count by 10% last year.

The Invus Group's People

NameTitleEmail/Phone
1
President and CEOReveal Email/Phone
2
CEO/PresidentReveal Email/Phone
3
VP FinanceReveal Email/Phone
4
VP, Private Equity, Asian Emerging MarketsReveal Email/Phone
5
Associate VP - FinanceReveal Email/Phone
6
DirectorReveal Email/Phone
7
Private Equity DirectorReveal Email/Phone
8
Managing DirectorReveal Email/Phone
9
Managing DirectorReveal Email/Phone
10
DirectorReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$3.5M11-39%N/AN/A
#2
$2.8M20-20%N/AN/A
#3
$7.5M7625%N/AN/A
#4
$11830M3846%$1MN/A
#5
$7.5M5512%$48.1MN/A
#6
$15M12917%N/AN/A
#7
$1.1M8-88%N/AN/A
#8
$2.7M19-21%N/AN/A
#9
$2.4M1713%N/AN/A
#10
$7.5M5520%N/AN/A
Add Company

What Is The Invus Group?

Evergreen structure with over $5 billion under management. Offices in New York, Paris, and Hong Kong.

keywords:N/A

N/A

Total Funding

89

Number of Employees

$15M

Revenue (est)

10%

Employee Growth %

N/A

Valuation

N/A

Accelerator

The Invus Group News

2022-04-17 - Biotech venture capital: Top 10 money-raisers of 2021

... Fidelity Management & Research Company, MPM Capital, F2 Ventures, Redmile Group, EcoR1 Capital, Samsara BioCapital, The Invus Group,...

2022-04-06 - Onxeo Reports its Full-Year 2021 Financial Results and ...

- Recurring revenues corresponding to royalties on sales received by the Group pursuant to the agreement with Biogen. In 2020, these revenues...

2022-03-30 - ACTION AGAINST HUNGER WELCOMES FOUR NEW ...

... and CEO of The Invus Group, LLC, a New York-based global investment firm. ... practices of its board of directors and executive team,...

2019-09-08 - US investor joins Achilles Therapeutics £100m Series B round

... by founding investor Syncona and joined by important new investors including Forbion, Invus, Perceptive Advisors and Redmile Group.

2019-09-07 - UK biotech secures £100m funding for lung cancer trials

Achilles Therapeutics, a UK biotech focusing on personalised immunotherapy for cancer, has closed a £100m Series B funding round that ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$12.9M89-14%N/A
#2
$28.9M89-3%N/A
#3
$21.6M89-25%$66.2M
#4
$15M89-14%N/A
#5
$12.9M896%N/A